Tumour regression after systemic administration of a novel targeted vitamin E therapeutic system

Tocotrienol, an extract of vitamin E, has been shown to exert antiproliferative and tumour suppressive effects on cancer cells.However, its therapeutic potential is currently limited by its failure to reach tumours after intravenous administration, without secondary effects on normal tissues. The objectives of this study are to prepare and characterise novel transferrin-targeted vesicles encapsulating tocotrienol, able to recognise transferrin receptors overexpressed on many cancer cell lines and to evaluate in vitro and in vivo the therapeutic and targeting efficacies of this therapeutic system.